Fexofenadine HCL Follow On
ID: SPE2D219D0077P00001Type: Special Notice
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/80c0b3d280fe475bbdb0239639f82d3f/view
Timeline
    Description

    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is procuring Fexofenadine HCL Follow On. Fexofenadine HCL is typically used as an antihistamine to relieve allergy symptoms such as watery eyes, runny nose, itching eyes/nose, sneezing, hives, and itching.

    Point(s) of Contact
    Catherine Gilbert
    (215) 737-4778
    catherine.gilbert@dla.mil
    Denise Taubman
    (215) 737-8677
    denise.taubman@dla.mil
    Files
    Title
    Posted
    Fexofenadine Mod P00001 - clause change SIGNED.pdf
    Lifecycle
    Title
    Type
    Fexofenadine HCL Follow On
    Currently viewing
    Special Notice
    Similar Opportunities
    Fexofenadine HCL Follow On MOD P00002
    Buyer not available
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is seeking Fexofenadine HCL Follow On MOD P00001. Fexofenadine HCL is a drug used to relieve symptoms of seasonal allergies such as runny nose, sneezing, itchy or watery eyes, and itching of the nose or throat. This procurement is for NDC changes. For more information, please contact Catherine Gilbert at catherine.gilbert@dla.mil or 2157374778.
    Famotidine
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Famotidine, a drug used to treat ulcers and gastroesophageal reflux disease (GERD). The contract will include Famotidine 20 MG tablets in various bottle sizes and Famotidine 40 MG tablets in different bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. The solicitation is expected to be posted on the DLA Bid Board System (DIBBS) and SAM.gov. For any questions or comments, interested parties should contact Kristen Baraniewicz. The projected solicitation date is August 2022, but DLA reserves the right to issue the solicitation before or after that date.
    Notice of Intent to Sole Source: Allergen Extract Supplies
    Buyer not available
    The Department of Defense, specifically the Department of the Army, intends to execute a Sole Source Award for allergen extract supplies to support the United States Army Centralized Allergen Extract Laboratory (USACAEL) at Fort Meade, Maryland. This procurement, valued at approximately $1.8 million, will involve a Firm Fixed Price contract with a performance period from August 16, 2025, to August 15, 2030, and may include a potential 6-month extension. The supplies are critical for managing allergies and food-related health issues, requiring the contractor to meet stringent FDA approval and USP compliance standards while demonstrating the ability to supply at least 98% of the requested allergen extracts. Interested parties should respond to the notice by contacting Alexis Medrano or Catherine-Tehila Johnson via the provided email addresses by the specified deadline.
    Doxycycline Hyclate
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Doxycycline Hyclate. The contract will establish a national supply source to provide Doxycycline Hyclate 100MG Tablets in various bottle sizes. This acquisition is for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be firm-fixed price, requirements type with a one year base and four one year options. Interested parties should contact Catherine Gilbert for more information. The projected solicitation date is September 2019.
    FMS Cache Rx Products
    Buyer not available
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (ASPR/ORM-SNS), is seeking qualified vendors to supply FMS Cache Rx Products through a Combined Synopsis/Solicitation. The procurement involves a range of pharmaceutical products, including both over-the-counter and prescription medications, with specific requirements for quantities, packaging types, and compliance with regulatory standards. This initiative is crucial for ensuring the availability of essential medical supplies for government facilities, thereby supporting public health services. Interested vendors should contact Terri Reed at terri.reed@hhs.gov or Kimberly Golden at kimberly.golden1@hhs.gov for further details and to participate in the bidding process.
    Telmisartan Tablets
    Buyer not available
    The Defense Logistics Agency (DLA) is soliciting proposals for the procurement of Telmisartan Tablets, a pharmaceutical product essential for various medical applications, under Solicitation No. SPE2D2-24-R-0015. The contract aims to secure a reliable supply of these tablets in multiple dosages over several years, emphasizing compliance with federal regulations, including the necessity for a Subcontracting Plan for large businesses and adherence to various Federal Acquisition Regulation (FAR) clauses. Interested contractors should note that the submission deadline has been extended to February 28, 2025, at 3:00 PM EST, and are encouraged to contact Courtney Hunter-Stangler at Courtney.Hunter-Stangler@dla.mil or Jason Wray at jason.wray@dla.mil for further inquiries.
    Rizatriptan Benzoate
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rizatriptan Benzoate tablets. The contract will establish a national supply source to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The solicitation will be posted on the DLA Bid Board System and SAM.gov. Interested parties should contact Keith Ryales for any questions/comments. The projected solicitation date is June 2022.
    Fluconazole - Modification P00005 to Contract
    Buyer not available
    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY - TROOP SUPPORT MEDICAL is seeking a modification to the contract for Fluconazole. Fluconazole is a medication used to treat and prevent fungal infections. The modification, P00005, will involve changing the National Drug Codes (NDCs) associated with the procurement.
    Fluconazole - SPE2D221-D-0125-P00012 - Final Option Notice
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA Troop Support), has issued a special notice regarding the contract modification for Fluconazole under contract number SPE2D221-D-0125-P00012. This modification announces the exercise of the final option for the procurement of this pharmaceutical product, which is critical for various medical applications within military healthcare. Interested parties can reach out to the primary contact, Courtney Hunter-Stangler, at Courtney.Hunter-Stangler@dla.mil or by phone at 215-737-6845, or to the secondary contact, Jason Wray, at jason.wray@dla.mil or 215-737-0614, for further details regarding this opportunity.
    Dimethyl Fumarate DR Presolicitation
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.